| [1] |
ZENG Lijie, WANG Liang, YANG Lei .
Clinical features and treatment efficacy analysis of central nervous system involvement in extranodal nasal-type natural killer/T-cell lymphoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 81-87.
|
| [2] |
LI Mengjiao, CEN Yali, DOU Baitao, SHU Rou, LI Yanling, QIU Ling, REN Shihui, YAO Hao, FAN Fangyi.
Advances in the application of molecular targeted drugs combined with CAR-T cell therapy in lymphoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 532-539.
|
| [3] |
LYU Liwei, CONG Jia, WU Yiping, WANG Liang .
BCMA CAR-T cell therapy for relapsed/refractory plasmablastic lymphoma: case report and clinical implication
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 562-565.
|
| [4] |
BI Jianghan, ZHANG Yan, WANG Wei .
Glofitamab therapy under the dual challenge of novel coronavirus infection and CAR-T resistance: a case report of refractory diffuse large B-cell lymphoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 566-570.
|
| [5] |
HE Ying, LI Mengjiao, CEN Yali, DOU Baitao, SHU Rou, LI Yanling, YAO Hao, FAN Fangyi.
CD19 CAR T-cell therapy: a case of refractory primary central nervous system diffuse large B-cell lymphoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 571-576.
|
| [6] |
YANG Lei, ZENG Lijie, TAO Jianhua, YAO Na, CONG Jia, YANG Jing, WANG Henan, WEI Liqiang, WANG Liang.
Clinical analysis of extranodal NK/T-cell lymphoma,nasal type,manifesting with primary ocular lesions
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(3): 321-326.
|
| [7] |
LIU Yue, QI Shunan, LI Yexiong.
Application of PD-1/PD-L1 inhibitors in extranodal natural killer/T-cell lymphoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(3): 346-353.
|
| [8] |
GUO Jia, WANG Chengji, LIANG Yuanzheng, WANG Liang.
Clinical analysis of rituximab-induced interstitial lung disease in newly treated patients with diffuse large B-cell lymphoma: A retrospective study of single-center
[J]. Chinese Journal of Oncology Prevention and Treatment, 2023, 15(4): 391-397.
|
| [9] |
ZHANG Xuefang, DIAO Xiaoli, WANG Shuzhen.
Primary ovarian diffuse large B⁃cell lymphoma: 4 cases report and literature review
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(6): 653-658.
|
| [10] |
FU Ruiying, LIU Xindi, LIANG Yuanzheng, LIU Xuelin, WANG Liang.
The role of lncRNA BCYRN1 in activation of glycolysis in extranodal NK/T⁃cell lymphoma and its mechanism
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(4): 370-377.
|
| [11] |
LUO Yanzhen, ZHOU Da, CHEN Sijing, LIAO Chengcheng, WANG Mingyue, TAN Xiaohong, KE Qing, CEN Hong.
Relationship between tumor⁃associated macrophages and prognosis of diffuse large B⁃cell lymphoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(1): 87-93.
|
| [12] |
LI Zhe, CEN Hong .
Research progress on the classification of diffuse large B-cell lymphoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(6): 672-676.
|
| [13] |
WANG Wei, ZHANG Yan, WEI Chong, ZHAO Danqing, ZHANG Wei, ZHOU Daobin .
Clinical features of splenic marginal zone lymphoma with MYD88 L265P mutation
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(3): 277-282.
|
| [14] |
CHEN Jiamei, LUO Bo, LUO Xixi, CAI Gaoke, DONG Zuokun, SHI Wei, CHEN Yongshun.
Clinical subtypes,diagnosis,treatment and prognosis of intravascular large B-cell lymphoma in China
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(3): 288-294.
|
| [15] |
WANG Liang, ZHOU Xuan, LIANG Xiaojie, HE Yingzhi.
A novel six-gene based prognostic model for patients with diffuse large B-cell lymphoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2020, 12(3): 328-334.
|
